February 08, 2011
A new study has shown that hypergonadal patients undergoing testosterone replacement therapy (TRT) do not experience increased risk of worsening prostate health and safety parameters compared with eugonadal age-matched controls. Hypergonadal patients (n = 154; baseline average age of 58 years) receiving injectable testosterone undecanoate (1000 mg) and 160 eugonadal subjects with a mean age of 59 years were monitored at baseline and 6-monthly intervals over a period of 42 months. At baseline, hypergonadal patients had lower prostate-specific antigen and prostate volumes (0.68 mcg/L and 25.6 mL vs. 2.42 mg/L and 38.4 mL, respectively, in the control group). TRT did not worsen lower urinary tract symptoms, benign prostatic hyperplasia risk or adverse events such as acute urinary retention or prostate surgery (Yassin, A.A. et al. 4th World Congress of Controversies in Urology (CURy) (Jan 27-30, Paris) 2011, Abstract).
For more information I recommend you to visit the references below.